Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Ciclosporin composition for treating hemolytic anemia and application of composition

A technology for hemolytic anemia and a composition, applied in the field of medicine, can solve the problems of strong adverse reaction effect, difficult long-term tolerance of patients, etc., achieves low side effects and adverse reaction rates, and increases safety, compliance, side effects and adverse reactions. rate reduction effect

Inactive Publication Date: 2020-06-09
JIANGSU JIUYANG BIOLOGICAL PHARMA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the treatment of such diseases often requires patients to take medicine for a long time, and the existing immunosuppressants generally have the disadvantages of strong adverse reactions and difficult long-term tolerance for patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ciclosporin composition for treating hemolytic anemia and application of composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Example 1 Efficacy test of montelukast sodium combined with cyclosporine on hemolytic anemia model rats

[0016] 50 Wistar rats, weighing 180-220 g. Breeding conditions: room temperature at 20-25°C, relative humidity at 38%-41%, artificial lighting, light and dark for 12 hours, solid common feed and tap water, free intake of food and water, good ventilation; clean indoor sanitation twice a day, keep indoor No obvious ammonia odor.

[0017] 50 rats were randomly divided into the following five groups: normal control group, model control group, MK group, CSA group, MK-CSA group, 10 rats in each group, half male and half male. After the rats were fed adaptively for one week, except the normal control group, the other groups were intraperitoneally injected with 2% acetylphenylhydrazine normal saline solution 0.2g / kg on the first day and the fourth day respectively, and the normal control group was injected with normal saline instead. On the same day after successful model...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition for treating hemolytic anemia and an application of the pharmaceutical composition. The active ingredient in the pharmaceutical composition is composed of montelukast sodium and ciclosporin, the montelukast sodium and the ciclosporin bring an obvious synergistic effect through different effect targets in the treatment of the hemolytic anemia, and the side effects and adverse reaction rate of the montelukast sodium are low, the dosage of the ciclosporin is only one-fifth of a conventional dosage, so that the cost of medication, side effects and adverse reaction rate are greatly reduced, and the safety and compliance of patient medication are increased.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a cyclosporine composition for treating hemolytic anemia and its application. Background technique [0002] Hemolytic anemia (hemolyticanemia, HA) refers to a type of anemia that occurs when red blood cell destruction is accelerated and bone marrow hematopoietic function is insufficient to compensate. Hemolysis is the process of destroying red blood cells and shortening their lifespan. The bone marrow has 6-8 times the compensatory ability of normal hematopoiesis. When the hemolysis exceeds the compensatory ability of the bone marrow, the anemia caused is hemolytic anemia; when hemolysis occurs and the bone marrow can compensate, there is no anemia, which is called hemolytic state ( hemolytic state). The root cause of hemolytic anemia is the shortened lifespan of red blood cells, and the reasons for the accelerated destruction of red blood cells can be summarized i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/13A61K31/47A61P7/06
CPCA61K31/47A61K38/13A61P7/06A61K2300/00
Inventor 沈万照黄晔唐静
Owner JIANGSU JIUYANG BIOLOGICAL PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com